Search results
Author(s):
Marc P Bonaca
Added:
4 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,…
View more
Author(s):
Vlado Perkovic
Added:
9 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Author(s):
Harriette Van Spall
,
Darren McGuire
Added:
2 weeks ago
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the…
View more
Author(s):
Harriette Van Spall
,
Tauben Averbuch
Added:
11 months ago
HFA 2024 — Dr Tauben Averbuch and Dr Harriette Van Spall (McMaster University, Hamilton, CA) discuss the findings from the PACT-HF trial. In this analysis of PACT-HF, investigators looked at long term sex-specific clinical outcomes and healthcare resource utilisation following hospitalisation for heart failure at 5 years.Findings shows that clinical outcomes and overall costs were similar between…
View more
ESC 24: The SCOFF Trial
Author(s):
David Ferreira
Added:
7 months ago
Video
Author(s):
Gregg Stone
Added:
2 months ago
THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical…
View more
IU Anesthesia Grand Rounds: Religiosity/Spirituality in Medicine
Author(s):
Ankur Kalra
,
Nandan S Anavekar
Added:
1 year ago
Podcast Episode
Author(s):
Amish Raval
Added:
1 week ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the…
View more
TCT 23: IFR SWEDEHEART
Author(s):
Matthias Gotberg
Added:
1 year ago
Video
Author(s):
Alexander Fanaroff
Added:
1 year ago
CRT 24 - Dr Alexander Fanaroff (Penn Medicine, US) joins us in this short interview to discuss the findings of a national cohort of patients with chronic limb-threatening ischemia, CLIPPER.The CLIPPER cohort includes the baseline data and outcomes of 1.13 million patients with chronic limb-threatening ischemia.Findings from the study showed that for individuals with a diagnosis to limb…
View more